Innate Financial Statements From 2010 to 2025

IPHA Stock  USD 1.95  0.07  3.47%   
Innate Pharma financial statements provide useful quarterly and yearly information to potential Innate Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Innate Pharma financial statements helps investors assess Innate Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Innate Pharma's valuation are summarized below:
Gross Profit
-19.9 M
Profit Margin
(1.01)
Market Capitalization
173 M
Enterprise Value Revenue
4.0483
Revenue
33.8 M
We have found one hundred twenty available fundamental trends for Innate Pharma, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Innate Pharma regular market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of March 19, 2025, Market Cap is expected to decline to about 180.2 M. In addition to that, Enterprise Value is expected to decline to about 154 M

Innate Pharma Total Revenue

30.18 Million

Check Innate Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Innate Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.1 M, Interest Expense of 1.1 M or Selling General Administrative of 13.7 M, as well as many indicators such as Price To Sales Ratio of 3.47, Dividend Yield of 0.0023 or PTB Ratio of 3.47. Innate financial statements analysis is a perfect complement when working with Innate Pharma Valuation or Volatility modules.
  
Check out the analysis of Innate Pharma Correlation against competitors.
For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.

Innate Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets188 M211.8 M208.9 M
Slightly volatile
Short and Long Term Debt Total48.2 M45.9 M19.1 M
Slightly volatile
Other Current Liabilities14.8 M17.4 M17.3 M
Pretty Stable
Total Current Liabilities48.6 M45.6 M55.3 M
Slightly volatile
Total Stockholder Equity81.7 M59.7 M82.8 M
Slightly volatile
Property Plant And Equipment Net7.9 M7.3 M7.9 M
Slightly volatile
Current Deferred Revenue6.4 M6.7 M22.3 M
Very volatile
Accounts Payable17 M9.8 M17 M
Pretty Stable
Cash84.5 M81.2 M95.4 M
Slightly volatile
Non Current Assets Total55.5 M41.6 M63.7 M
Slightly volatile
Cash And Short Term Investments106.4 M106.3 M113.9 M
Slightly volatile
Common Stock Total Equity2.5 M4.5 MM
Slightly volatile
Common Stock Shares Outstanding53.1 M92.5 M58.2 M
Slightly volatile
Short Term Investments16.8 M19.7 M17.9 M
Pretty Stable
Liabilities And Stockholders Equity188 M211.8 M208.9 M
Slightly volatile
Non Current Liabilities Total57.7 M106.6 M70.8 M
Slightly volatile
Other Stockholder Equity464 M441.9 M261.5 M
Slightly volatile
Total Liabilities106.3 M152.1 M126.1 M
Slightly volatile
Property Plant And Equipment GrossM9.8 M8.2 M
Slightly volatile
Total Current Assets132.5 M170.2 M145.2 M
Slightly volatile
Short Term Debt10.8 M10.3 M5.5 M
Slightly volatile
Common Stock2.8 M4.7 MM
Slightly volatile
Net Receivables21.7 M17.5 M19.8 M
Very volatile
Intangible Assets454.5 K478.4 K25.5 M
Pretty Stable
Other Liabilities74.7 M65 M117.8 M
Slightly volatile
Net Tangible Assets84.3 M60.5 M71.8 M
Very volatile
Long Term Debt37 M35.2 M12.5 M
Slightly volatile
Long Term Investments8.4 M8.8 M32.7 M
Slightly volatile
Short and Long Term Debt5.6 M9.7 M3.8 M
Slightly volatile
Property Plant Equipment10.9 M9.8 M8.9 M
Slightly volatile
Net Invested Capital110.1 M81.9 M111.1 M
Pretty Stable
Net Working Capital109.1 M124.6 M85.8 M
Slightly volatile
Capital Stock4.2 M4.7 M3.6 M
Slightly volatile

Innate Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.1 M5.9 M4.8 M
Slightly volatile
Selling General Administrative13.7 M13.5 M13.7 M
Slightly volatile
Selling And Marketing Expenses4.1 M6.1 M3.5 M
Slightly volatile
Total Revenue30.2 M59.7 M35.4 M
Slightly volatile
Other Operating Expenses43.9 M74.3 M48.4 M
Slightly volatile
Total Operating Expenses78 M74.3 M42.8 M
Slightly volatile
Research Development51.5 M64.4 M42.9 M
Slightly volatile
Reconciled Depreciation5.6 M5.9 M11.4 M
Slightly volatile
Interest Income4.6 M3.7 M2.7 M
Slightly volatile

Innate Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.1 M4.9 M2.7 M
Slightly volatile
Begin Period Cash Flow81 M96.9 M94.3 M
Slightly volatile
DepreciationM5.9 M10.4 M
Slightly volatile
Capital Expenditures2.6 M2.7 M7.2 M
Pretty Stable
End Period Cash Flow84.5 M81.2 M95.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.473.6658.8077
Pretty Stable
Dividend Yield0.00230.00250.0032
Slightly volatile
PTB Ratio3.473.6612.5125
Pretty Stable
Days Sales Outstanding212376175
Pretty Stable
Book Value Per Share0.70.741.2509
Pretty Stable
Stock Based Compensation To Revenue0.130.09430.11
Very volatile
Capex To Depreciation0.50.531.0545
Pretty Stable
PB Ratio3.473.6612.5125
Pretty Stable
EV To Sales2.973.1252.3291
Pretty Stable
Payables Turnover6.185.892.9715
Slightly volatile
Sales General And Administrative To Revenue0.250.261.3449
Pretty Stable
Research And Ddevelopement To Revenue1.181.242.794
Pretty Stable
Capex To Revenue0.03870.04080.3125
Pretty Stable
Cash Per Share2.071.321.8516
Very volatile
Days Payables Outstanding60.9464.14230
Slightly volatile
Intangibles To Total Assets0.00250.00260.0813
Very volatile
Current Ratio4.684.293.8949
Slightly volatile
Tangible Book Value Per Share1.340.740.9916
Pretty Stable
Receivables Turnover0.951.05.6322
Pretty Stable
Shareholders Equity Per Share0.70.741.2509
Pretty Stable
Debt To Equity0.730.690.2933
Slightly volatile
Capex Per Share0.0250.02630.1031
Very volatile
Revenue Per Share0.370.580.486
Pretty Stable
Interest Debt Per Share0.480.450.2516
Slightly volatile
Debt To Assets0.20.190.1011
Slightly volatile
Graham Number2.62.12.3624
Slightly volatile
Price Book Value Ratio3.473.6612.5125
Pretty Stable
Days Of Payables Outstanding60.9464.14230
Slightly volatile
Company Equity Multiplier1.763.192.499
Slightly volatile
Long Term Debt To Capitalization0.350.330.118
Slightly volatile
Total Debt To Capitalization0.410.390.1895
Slightly volatile
Debt Equity Ratio0.730.690.2933
Slightly volatile
Quick Ratio4.654.293.8683
Slightly volatile
Net Income Per E B T1.461.545.9299
Pretty Stable
Cash Ratio1.851.62.2729
Slightly volatile
Days Of Sales Outstanding212376175
Pretty Stable
Price To Book Ratio3.473.6612.5125
Pretty Stable
Fixed Asset Turnover7.767.394.3401
Slightly volatile
Debt Ratio0.20.190.1011
Slightly volatile
Price Sales Ratio3.473.6658.8077
Pretty Stable
Asset Turnover0.130.250.1627
Slightly volatile
Price Fair Value3.473.6612.5125
Pretty Stable

Innate Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap180.2 M189.7 M1.7 B
Pretty Stable
Enterprise Value154 M162.1 M1.6 B
Pretty Stable

Innate Fundamental Market Drivers

Cash And Short Term Investments92.5 M

Innate Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Innate Pharma Financial Statements

Innate Pharma stakeholders use historical fundamental indicators, such as Innate Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Innate Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Innate Pharma's assets and liabilities are reflected in the revenues and expenses on Innate Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Innate Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue6.7 M6.4 M
Total Revenue59.7 M30.2 M
Cost Of Revenue64.4 M39.7 M
Stock Based Compensation To Revenue 0.09  0.13 
Sales General And Administrative To Revenue 0.26  0.25 
Research And Ddevelopement To Revenue 1.24  1.18 
Capex To Revenue 0.04  0.04 
Revenue Per Share 0.58  0.37 
Ebit Per Revenue(0.22)(0.23)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:
Check out the analysis of Innate Pharma Correlation against competitors.
For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.75)
Earnings Share
(0.46)
Revenue Per Share
0.419
Quarterly Revenue Growth
(0.69)
Return On Assets
(0.14)
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.